Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Hangzhou Biotest Biotech Co's annualizedNet Income for the quarter that ended in Mar. 2026 was ¥-40.8 Mil.
Hangzhou Biotest Biotech Co's average Total Assets over the quarter that ended in Mar. 2026 was ¥2,512.7 Mil. Therefore, Hangzhou Biotest Biotech Co's annualized ROA % for the quarter that ended in Mar. 2026 was -1.63%.
The historical rank and industry rank for Hangzhou Biotest Biotech Co's ROA % or its related term are showing as below:
SHSE:688767'
s ROA % Range Over the Past 10 Years
Min: 1.21 Med: 13.4 Max: 101.97
Current: 1.21
During the past 9 years, Hangzhou Biotest Biotech Co's highest ROA % was 101.97%. The lowest was 1.21%. And the median was 13.40%.
SHSE:688767's ROA % is ranked better than 82.63% of 1416
companies
in the Biotechnology industry
Industry Median: -32.985
vs SHSE:688767: 1.21
Hangzhou Biotest Biotech Co (SHSE:688767) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Hangzhou Biotest Biotech Co's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Biotest Biotech Co ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hangzhou Biotest Biotech Co's ROA % distribution charts can be found below:
* The bar in red indicates where Hangzhou Biotest Biotech Co's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Hangzhou Biotest Biotech Co (SHSE:688767) has a ROA % of -1.63% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Hangzhou Biotest Biotech Co and its competitors. Over the past decade, Hangzhou Biotest Biotech Co's ROA % has ranged from 1.21 to 101.97. According to the industry distribution chart, Hangzhou Biotest Biotech Co ranks #246 out of 1416 companies in the Biotechnology industry, placing it in the top 17.4%.
Is Hangzhou Biotest Biotech Co's ROA % too high?
Hangzhou Biotest Biotech Co's current ROA % is -1.63%. Over the past 10 years, this metric has ranged from a low of 1.21 to a high of 101.97. Based on the distribution chart, Hangzhou Biotest Biotech Co ranks #246 out of 1416 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hangzhou Biotest Biotech Co has a GF Score™ of 71/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Biotest Biotech Co's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hangzhou Biotest Biotech Co ranks #246 out of 1416 companies for ROA %. This places Hangzhou Biotest Biotech Co in the top 17% of its industry — outperforming the majority of peers. Historically, Hangzhou Biotest Biotech Co's own ROA % has ranged from 1.21 to 101.97 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Hangzhou Biotest Biotech Co and its competitors. Hangzhou Biotest Biotech Co's current ROA % is -1.63%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Biotest Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Biotest Biotech Co (SHSE:688767) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥26.87, compared to a current price of ¥34.50 — trading 28.4% above its estimated fair value. The current ROA % is -1.63%. Hangzhou Biotest Biotech Co's overall GF Score™ is 71/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Hangzhou Biotest Biotech Co (SHSE:688767), the current ROA % is -1.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Biotest Biotech Co (SHSE:688767) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Biotest Biotech Co stock appears to be overvalued.
The current stock price of ¥34.50 is trading 28.4% above its estimated GF Value™ of ¥26.87.
GuruFocus considers Hangzhou Biotest Biotech Co to be Modestly Overvalued.
Key valuation signals for SHSE:688767:
ROA %: -1.63%
GF Value™: ¥26.87 vs. price of ¥34.50 (28.4% above fair value)
No single metric tells the full story. See the SHSE:688767 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou Biotest Biotech Co Ltd is engaged in the research and development, manufacturing, sales and service of in vitro diagnostic reagents, raw materials and instruments.
71GF Score
Get the complete analysis for SHSE:688767
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688767 has been successfully added to your 
